Ingredient supplier Niagen Bioscience, formerly known as Chromadex, is once again under the microscope of the Better Business Bureau’s (BBB) National Advertising Division (NAD). The NAD has issued a recommendation that Tru Niagen, Niagen’s consumer-facing dietary supplement brand, either modify or cease certain advertising claims pertaining to the levels of nicotinamide adenine dinucleotide (NAD+) and associated health benefits. This development follows a challenge lodged by a competitor, Reus Research, and occurs in the wake of a partial victory for Niagen in a separate advertising dispute with Reus.
The NAD’s decision, released following a thorough review, addresses a spectrum of claims made by Tru Niagen. According to the NAD’s statement, Reus Research specifically challenged assertions that the brand’s advertising conveyed unsupported messages regarding:
- Increases in NAD+ levels.
- Organ-specific health benefits.
- Broader vitality and anti-aging effects.
- Cellular-level benefits.
- Consumer-perceptible effects.
- The use of consumer testimonials and influencer marketing practices.
Reus Research bolstered its challenge by submitting a warning letter from the U.S. Food and Drug Administration (FDA) and three court decisions. In response, Niagen presented a substantial body of clinical research focusing on oral nicotinamide riboside (NR) supplementation, the active ingredient in Tru Niagen, and its role in human physiology.
Background: The NAD and its Role in Advertising Review
The National Advertising Division of the BBB is a self-regulatory body that operates within the advertising industry. Its primary function is to promote truthfulness and accuracy in national advertising. When a complaint is filed, the NAD reviews the advertising in question and the substantiation provided by the advertiser. If the NAD finds that the advertising is not adequately substantiated, it will recommend that the advertiser modify or discontinue the challenged claims. While the NAD’s recommendations are not legally binding, advertisers typically comply to avoid further scrutiny from the Federal Trade Commission (FTC), which can take enforcement action.
This process is particularly relevant for the dietary supplement industry, which operates under the Dietary Supplement Health and Education Act of 1994 (DSHEA). DSHEA allows for structure/function claims, which describe the role of a nutrient or dietary ingredient intended to affect the normal structure or function in humans, provided these claims are truthful and not misleading. However, these claims must be substantiated by competent and reliable scientific evidence. Claims of disease prevention or treatment are prohibited and fall under the purview of the FDA.
The NAD’s Findings on Tru Niagen’s Claims
The NAD acknowledged that current clinical evidence indicates that nicotinamide riboside (NR) can indeed increase NAD+ levels under specific conditions. However, the advertising board concluded that the cumulative differences in study designs, the specific endpoints measured, and the varied populations tested across the available research did not sufficiently support a broad "clinically proven" assertion for all of Tru Niagen’s claims.
This distinction is crucial. While individual studies might show positive results in specific contexts, the NAD’s evaluation often looks for a consensus of evidence or robust meta-analyses to support sweeping claims that suggest universal efficacy or a definitive "proven" status. The NAD’s decision suggests that the evidence, while promising for NR’s ability to boost NAD+ levels, may not yet be comprehensive enough to undergird the extensive and broad-reaching claims made by Tru Niagen across multiple health domains.
A Contentious Landscape: Reus Research and Previous Rulings
The current NAD review is not the first instance of regulatory scrutiny for Niagen Bioscience. The company has been involved in a back-and-forth with its competitor, Reus Research, regarding advertising practices. Hank Schultz previously reported for SupplySide Supplement Journal on a partial win for Niagen, where it successfully challenged NAD+ content claims made by Reus. This inter-company dispute highlights the competitive and often litigious environment within the supplement industry, where companies actively monitor and challenge each other’s marketing strategies.
The NAD’s decision in the current case appears to stem from a comprehensive challenge by Reus, which leveraged a range of evidence, including regulatory actions and judicial decisions. Niagen’s defense, conversely, relied heavily on its extensive clinical trial data concerning NR and NAD+. The NAD’s role is to objectively assess this evidence against established advertising standards.
Niagen’s Response and Planned Appeal
Niagen Bioscience has indicated its intention to appeal the BBB National Advertising Division’s decision. Carlos Lopez, Senior Vice President and General Counsel at Niagen, expressed strong disagreement with the NAD’s findings, stating that the decision deviates from established precedents set by regulatory bodies like the FDA and FTC, as well as judicial interpretations governing dietary supplement advertising.
Lopez articulated Niagen’s position on the NAD’s methodology: "It misapplies the substantiation standard by incorrectly recategorizing qualified cellular and structure/function statements into broader implied claims, and by critiquing individual studies in isolation instead of evaluating the totality of the evidence through an appropriately scientific lens." This suggests Niagen believes the NAD has overstepped its bounds by reinterpreting valid scientific claims as broader, unsubstantiated implications and by dissecting research in a manner that Niagen deems unscientific.
Furthermore, Lopez questioned the appropriateness of the NAD as a forum for evaluating dietary supplement advertising, implying that the organization may not possess the specialized expertise required to navigate the complexities of nutraceutical claims. He characterized the decision as one that "undermines settled supplement precedent, ignores DSHEA principles, and fundamentally alters substantiation requirements for structure/function claims." This statement underscores Niagen’s concern that the NAD’s ruling could set a problematic precedent for the entire industry.
Despite its intent to appeal, Niagen has also stated that it has established procedures to ensure content creators adhere to legal requirements. According to Lopez, the company has agreed to comply with NAD’s recommendations on this specific matter, pending the outcome of its appeal. This dual approach – challenging the decision while acknowledging a commitment to compliance – is a common strategy in such regulatory disputes.
Broader Implications for the Dietary Supplement Industry
The NAD’s decision regarding Tru Niagen has potential ramifications for the broader dietary supplement market, particularly for brands marketing ingredients that influence cellular metabolism and aging. NAD+ is a critical coenzyme involved in hundreds of metabolic processes, and its decline with age has been linked to various age-related conditions. This has led to a surge in interest and marketing around NAD+ boosting supplements.
If the NAD’s interpretation of substantiation standards for NAD+ related claims becomes more stringent, it could impact how other companies in this space formulate and advertise their products. The emphasis on the "totality of the evidence" and the careful distinction between qualified structure/function claims and broad, implied claims will likely be points of contention and careful consideration for advertisers.
The legal and regulatory landscape for dietary supplements is constantly evolving. Companies must navigate a complex web of regulations from the FDA, FTC, and self-regulatory bodies like the NAD. The ongoing dialogue between these entities, advertisers, and scientific researchers is essential for ensuring that consumers receive accurate information about the products they choose to use for their health and well-being.
Niagen Bioscience’s appeal will be closely watched by industry stakeholders. The outcome could influence how NAD+ boosting supplements, and potentially other science-backed ingredients with complex physiological effects, are marketed in the future. The case highlights the ongoing challenge of balancing innovative health claims with the need for robust scientific evidence and clear, transparent communication with consumers.
The Science Behind NAD+ and Nicotinamide Riboside
Nicotinamide adenine dinucleotide (NAD+) is a vital molecule found in all living cells. It plays a crucial role in energy metabolism, DNA repair, and cellular signaling. As humans age, NAD+ levels naturally decline, which has been associated with a range of age-related physiological changes and diseases. This scientific understanding has fueled significant research into ways to boost NAD+ levels, particularly through dietary interventions.
Nicotinamide riboside (NR) is a form of vitamin B3 that has garnered considerable attention for its ability to serve as a precursor to NAD+. When ingested, NR is converted into NAD+ within the body. Clinical studies have explored the efficacy of NR supplementation in increasing NAD+ levels in humans. Research published in journals such as Nature Communications and the American Journal of Clinical Nutrition has demonstrated that NR supplementation can indeed elevate NAD+ levels in various tissues, including muscle and blood.
However, the precise mechanisms by which elevated NAD+ impacts specific organ functions, overall vitality, or the aging process are still subjects of ongoing scientific investigation. While preclinical studies in animal models have shown promising results, translating these findings directly to broad human health claims requires rigorous and well-designed clinical trials in diverse human populations.
The NAD’s decision reflects a common challenge in translating complex scientific findings into consumer-facing marketing. While scientific research may establish a link between an ingredient and a biological effect (like increasing NAD+ levels), the leap to claiming specific, broad health benefits (like anti-aging or enhanced organ function) often requires a higher burden of proof, including evidence of measurable, consumer-perceptible outcomes.
Navigating the Regulatory Framework: DSHEA and Structure/Function Claims
The Dietary Supplement Health and Education Act of 1994 (DSHEA) is the foundational legislation governing dietary supplements in the United States. Under DSHEA, manufacturers are responsible for ensuring that their products are safe and that any claims made about them are truthful and not misleading.
A key distinction within DSHEA is the allowance for "structure/function" claims. These claims describe the role of a nutrient or dietary ingredient intended to affect the normal structure or function in humans. For example, a claim that calcium builds strong bones is a structure/function claim. These claims are permissible as long as they are not disease claims (e.g., "treats osteoporosis") and are substantiated by competent and reliable scientific evidence.
The NAD’s review of Tru Niagen’s advertising centers on whether the claims made meet this substantiation threshold. The challenge lies in interpreting what constitutes "competent and reliable scientific evidence" for complex biological processes and the multifaceted nature of aging. The NAD’s recommendation suggests that while Niagen may have evidence for NR increasing NAD+ levels, the leap to broader health benefits may not be sufficiently supported by the current scientific literature in a way that allows for unqualified "clinically proven" assertions.
Niagen’s assertion that the NAD decision "misapplies the substantiation standard by incorrectly recategorizing qualified cellular and structure/function statements into broader implied claims" speaks to this intricate regulatory balance. Niagen likely believes its claims, when properly interpreted, fall within the permissible scope of structure/function claims and are adequately supported. The NAD’s counter-argument implies that the breadth and implication of these claims extend beyond what the presented evidence can rigorously support.
The Role of Self-Regulation in the Supplement Industry
The NAD operates as a vital component of the advertising industry’s self-regulatory system. By offering a mechanism for reviewing advertising claims and resolving disputes, it aims to foster a more ethical and transparent marketplace. This self-regulatory approach is often seen as a way to preempt more heavy-handed government intervention.
Companies like Niagen Bioscience, while sometimes at odds with NAD decisions, generally engage with the process because of the potential downstream consequences of non-compliance. An adverse NAD decision can lead to an FTC investigation, which carries the weight of legal enforcement and potential penalties. Therefore, even when disagreeing with a recommendation, compliance or a well-reasoned appeal is typically the preferred course of action.
The NAD’s involvement in this case underscores the importance of rigorous substantiation for health-related claims, especially in a rapidly growing market like NAD+ boosters. As scientific understanding of these compounds evolves, so too must the advertising claims made about them, ensuring they align with both scientific evidence and regulatory expectations. The ongoing dialogue between Niagen and the NAD, as well as Niagen’s planned appeal, will be crucial in shaping the future of advertising for this category of supplements.